Spots Global Cancer Trial Database for Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
Official Title: Lipiodol Deposition in Hypervascular Tumors: Endhole vs. Pressure-modulated Delivery
Study ID: NCT06204159
Interventions
Study Description
Brief Summary: The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE. • Is there a difference in CT appearance with delivery in the type of catheter used during the TACE procedure? Participants will be asked to undergo a TACE procedure, a CT scan and review of their medical record to compare End Hole and TriNav catheters during TACE procedures.
Detailed Description: Hepatocellular (HCC) and neuroendocrine (NET) liver metastases undergoing Lipiodol transarterial chemoembolization (TACE) will be randomized to endhole vs. pressure-modulated catheter delivery. Lipiodol deposition will be quantified and correlated with volumetric necrosis, response, and local progression.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Pennsylvania, Department of Radiology, Interventional Radiology Division, Philadelphia, Pennsylvania, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
